The Skin Hospital (Skin & Cancer Foundation Australia)

Condition(s): Cancer, Skin

ADDRESS: 7 Ashley Lane, WESTMEAD SYDNEY NSW 2145 / 121 Crown St, DARLINGHURST SYDNEY NSW 2010
POSTAL ADDRESS: 121 Crown St, DARLINGHURST SYDNEY NSW 2010
PHONE: (02) 8833 3000 Westmead / (02) 8651 2000 Darlinghurst
WEBSITE: Visit Website

Name: Dr Minal Dalvi
Role:  Director/Unit Manager
Phone: (02) 8833 3096
Email: mdalvi@skinhospital.edu.au

Name: Caitlin Purcell
Role: Study Coordinator
Phone: (02) 8833 3023
Email: cpurcell@skinhospital.edu.au

Name: Dr Naomi Sinclair
Role: Study Coordinator
Phone: (02) 8651 2027
Email: nsinclair@skinhospital.edu.au




Monday: 09:00 – 17:00

Tuesday: 09:00 – 17:00

Wednesday: 09:00 – 17:00

Thursday: 09:00 – 17:00

Friday: 09:00 – 17:00

Saturday: Closed

Sunday: Closed

COVID INFO

Formerly called the Skin & Cancer Foundation Australia, The Skin Hospital was established in 1976 to provide a training and research facility for the development of academic dermatology in Australia. Forty years on the hospital is now a leading facility in Australia for Dermatological Clinical Services, Education and Research & Clinical Trials.

The Skin Hospital is committed to undertaking research in dermatology. We have a dedicated research unit under the leadership of A/Prof Gayle Fisher backed up by a highly skilled research team. The Skin Hospital has over 10 years of experience in the management of clinical trials. As patient safety is our main priority, all our clinical trials are thoroughly reviewed and approved by an external ethics committee.

Our dedicated team are experts in conducting dermatological clinical trials, from Phase I through to Phase IV, including pharmaceutical and device trials. Their extensive experience and commitment to each trial allows for the collection of valuable research, furthering the development of potential treatments for various skin conditions.

Our state-of-the-art facilities include exclusive clinical consultation rooms, across our Darlinghurst and Westmead hospitals. All members of our clinical trials team are focused on ensuring the best service and results for participants.

CURRENT CLINICAL TRIALS

JOBS (CURRENT OPEN POSITIONS)

No current jobs

SITE EXPERIENCE

Protocol title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparatorcontrolled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis
Registry: ClinicalTrials.gov
Registry #: NCT02207231
Link to registry: See Registry

Protocol title: A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Adolescents and Adults With Scalp and Body Psoriasis
Registry: ClinicalTrials.gov
Registry #: NCT04128007
Link to registry: See Registry

Protocol title: A phase 2b, double-blind, randomised, 5-arm, vehicle-controlled, dose-ranging trial to evaluate the efficacy and safety of twice daily topical applications of delgocitinib cream 1, 3, 8, 20 mg/g for 8 weeks in adult subjects with mild to severe atopic dermatitis
Registry: ClinicalTrials.gov
Registry #: NCT03725722
Link to registry: See Registry

Protocol title: A randomised, double-blind, placebo-controlled, parallel-group, multi-centre trial to evaluate the efficacy, safety, and tolerability of tralokinumab monotherapy in adolescent subjects with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.
Registry: ClinicalTrials.gov
Registry #: NCT03526861
Link to registry: See Registry

Protocol title: A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis
Registry: ClinicalTrials.gov
Registry #: NCT03738397
Link to registry: See Registry

Protocol title: A Phase 2b Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 With A Partially Blinded Extension Period To Evaluate The Efficacy And Safety Of Pf-06651600 And Pf-06700841 In Subjects With Active Non-segmental Vitiligo
Registry: ClinicalTrials.gov
Registry #: NCT03715829
Link to registry: See Registry

Protocol title: A Phase 3 Multi-center, Long-term Extension Study Investigating the Efficacy and Safety of Abrocitinib, With or Without Topical Medications, Administered to Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
Registry: ClinicalTrials.gov
Registry #: NCT03422822
Link to registry: See Registry

Protocol title: A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata
Registry: ClinicalTrials.gov
Registry #: NCT03899259
Link to registry: See Registry

Protocol title: A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients with Atopic Dermatitis
Registry: ClinicalTrials.gov
Registry #: NCT03334435
Link to registry: See Registry

Want access to more Site details?

Sponsors and CROs looking to choose Sites for their next clinical trial are encouraged to sign up to AustralianClinicalTrials.com. In doing so, you will get free access to any and all Site Selection Packages, ready for you to download. Curated by Sites themselves, all the information you need to know for selection is presented in an easy to read format, saving you time and money. Create an account, and become a part of the fastest growing clinical trials community today!